British Journal of Dermatology

Article	Citations
Living with vulval lichen sclerosus: a qualitative interview study	269
Integrating artificial intelligence into skin cancer pathways: the opportunities and obstacles	218
352 Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: a post-hoc analysis of the JADE REGIMEN phase 3 trial	176
335 Improvement in sleep quality, anxiety and depression in adults with moderate-to-severe atopic dermatitis with dupilumab treatment	89
Greater understanding about differences in the long-term course of eczema and their risk factors in children	81
Epidemiology, comorbidities and mortality of pyoderma gangrenosum: new insights	74
520 - Evaluating the expression of OX40 and OX40 ligand in lesional skin versus non-lesional skin in volunteers with atopic dermatitis and in healthy control skin	72
561 - Dupilumab treatment reduces signs in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial	71
Relationship between atopic dermatitis, depression and anxiety: a two‐sample Mendelian randomization study	70
Higher proportion of cellulitis in severe lymphoedema	68
COVID-19 vaccines and skin manifestations	67
677 - Establishing a patient-centered definition of atopic dermatitis flare: insights from a modified eDelphi study	66
691 - Understanding patient and physician preferences when choosing between biologic and oral systemic treatment options for moderate-to-severe atopic dermatitis: a discrete choice experiment	66
643 - Effectiveness and safety of upadacitinib in adolescent and adult patients with atopic dermatitis: an analysis of short-term (week 8-20) data from a real-world multicenter retrospective review	64
673 - Efficacy of nemolizumab in different subgroups of patients with prurigo nodularis in two randomized, placebo-controlled phase 3 trials	62
641 - Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis	61
603 - Ruxolitinib cream 1.5% twice daily for the treatment of extensive atopic dermatitis in children aged 2–11 years: 52 week results from a maximum-use trial	59
粒细胞集落刺激因子在化脓性汗腺炎中的作用	58
P51: Socioeconomic factors influence severity rather than incidence of dermatoses	57
PS04: Burden of treatment in adult patients with atopic dermatitis	57
P79: A review of proton pump inhibitor photosensitivity in a tertiary referral photodiagnostic centre	56
BH08: A rare and incidental finding of pili multigemini of the back	56
PA07: Scratching the surface: a review of online misinformation and conspiracy theories in paediatric atopic dermatitis	55
PD16: Behaviours, attitudes and the importance of sun safety via an Arduino development kit	54
一项在一家大型教学医院进行的 5 年皮肤附属器肿瘤研究, 对关联基因诊断提供了启示	51

对化疗所致脱发的更深入了解	51
空气污染会导致皮肤颜色变深	49
The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa	49
BG02: Muir‐Torre syndrome: a case of unusual coexisting genetic mutations	48
BT06: Reporting time in two different teledermatology platforms	48
Understanding itch in epidermolysis bullosa (EB)	48
How do dermatologists’ personal models inform a patient‐centred approach to management: a qualitative study using the example of prescribing a new treatment (Apremilast)*	46
P15: Twenty years of the UK Dermatology Clinical Trials Network: past, present and future	46
Recognizing psoriasis in children and adolescents: the DIPSOC study	46
BH13: Scarring alopecia affecting a congenital melanocytic naevus in a patient with frontal fibrosing alopecia	46
P100: Efficacy of current treatments under study in patients with alopecia areata	46
CPC11: Bromoderma in a patient with chronic obstructive pulmonary disease	45
开展健康宣传活动，禁售日光浴床，以减少皮肤癌: 合理利用医疗预算	43
BH09: Frontal fibrosing alopecia in men: is it any different?	43
P57: New order: redesigning referral pathways to improve access for patients from dermatology outpatient waiting lists	43
H10: A Sweet diagnosis to make: the history of Robert Douglas Sweet and acute febrile neutrophilic dermatosis	43
P52: Opportunities for implementing a patient‐initiated follow‐up pathway in patients with psoriasis completing narrowband ultraviolet B phototherapy	42
Issue Information	41
Issue Information	41
PS11: Severe suicidal attempt secondary to allergic contact dermatitis in a noncompliant patient	40
Eligibility criteria for programmed death receptor 1 inhibitors vs. real‐world advice: a retrospective analysis of 69 patients with advanced cutaneous squamous cell carcinoma of the head and neck	40
News and Notices	40
DP27: Maculopapular cutaneous mastocytosis mimicking seborrhoeic folliculitis	39
Possible new oral treatment for hidradenitis suppurativa	39
BT08: Assessment of three different dermoscopy imaging systems during a fast‐track skin cancer clinic	39
P53: Office 365: Microsoft Lists as a tool for a secure online second‐line/systemic drug database	38
皮肤红斑狼疮治疗指南	38
How can we best use scoring scales that can be completed in clinic for assessing improvements in the severity of eczema?	37
DP12: An 11‐year mystery	37
P79 A multidisciplinary expert consensus on the assessment of and support for mental health in children and young people living with skin conditions	36
P91: Cutaneous adverse events of immune check point inhibitors nivolumab, pembrolizumab and atezolizumab: a multicentric study	36
H15 A treatment for leprosy developed on the edge of Europe: Vincent Barry (1908–1975)	35
P67 Overall lifetime risk for alopecia areata is 2.1% and is higher in women, non-White ethnic groups and the most deprived: a UK population-based cohort study	35
CD03 Contact sensitization to shellac: a possible marker of fragrance allergy	35
BT12 A comparison of outcomes and cost-effectiveness in a teledermatology vs. a standard face-to-face 2-week wait UK model	35
PA24 Abnormal interferon signature in a patient with chilblain lupus	34
DP21 Thymoma and the skin: manifestations of multiorgan autoimmunity	34
H17 Traditional medicine: a warts-and-all tale	34
Editor's Choice – John Ingram – Sep 2023	33
DP22 Cutaneous lymphoid hyperplasia: clinicopathological correlation and a therapeutic option	33
Can brepocitinib be formulated into an effective topical therapy to treat mild-to-moderate chronic plaque psoriasis?	33
BI08 Defining the burden of mucocutaneous disease in organ transplant recipients living with HIV: the Mucocutaneous disorders in Organ Transplant recipients living with HIV study	33
Correction	32
010 Enhanced outcome prediction in cutaneous squamous cell carcinoma using deep-learning and computational histopathology (cSCCnet)	32
银屑病皮肤细胞中的小分子 RNA 促进炎症发生	32
P13 A rare case of Sjögren syndrome in a White woman with Kikuchi–Fujimoto disease	32
005 Association between prescription drugs and vaccines commonly prescribed to older people and bullous pemphigoid: a UK population-based study	32
CPC02 Delayed widespread lichenoid drug reaction with radioisotopic response in a patient treated with nivolumab	31
BI26 Treatment-induced scleroderma in a patient with metastatic melanoma	31
O22 Unravelling the pathophysiology of KLICK syndrome to identify therapeutically targetable pathways	31

P50 Exploring unmet needs and attitudes to skin self-examination in melanoma survivors: EUNASS study	31
Adding up the desmosomal genes causing syndromes with hair and skin involvement: identification of TUFT1 by state-of-the-art whole-genome sequencing	30
Atypical melanocytes of an atypical Spitz tumour observed with optical super-high magnification dermoscopy	30
Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6–11 years with severe atopic dermatitis	30
Mosaic EGFR exon 20 in-frame insertion pathogenic variants are associated with papular epidermal naevus with ‘skyline’ basal cell layer (PENS)	30
Occupational skin cancer: measurements of ultraviolet radiation exposure bring knowledge for prevention	30
Mainstreaming genetic testing in dermatology in the UK	30
Incidence, mortality and survival in people with Merkel cell carcinoma: a systematic review	30
Comparison of incidence, causes and prognosis of adult and paediatric epidermal necrolysis: a French population-based study	30
Development of a shared decision-making tool in vitiligo: an international study	30
How to score the impact of treatment on cutaneous neurofibromas in clinical trials	29
Delusional infestation – do not be scared!	29
Multicentre phase II trial of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab in Japanese advanced melanoma patients: immune resistance remains one of the major efforts in melanoma	29
Successful treatment of severe subcorneal pustular dermatosis with the 308-nm ultraviolet B excimer laser	29
Neutrophil infiltration in allergic contact dermatitis to nickel	29
Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study	29
O11 The human discs large protein (Dlg1) controls connexin 43 (Cx43) plasma membrane localization and gap junctional communication in keratinocytes	29
Seeking new topical therapies in psoriasis	29
The association of anxiety with granuloma annulare: a case–control study of the National Institutes of Health ‘All of Us’ research programme	29
Interactive effect of genetic and environmental risk factors on psoriasis: current evidence and future directives	29
O06 Exploring host–microbiome–immune interactions using singular and multispecies inoculations in optimized 3D skin models	29
P19 The association between psoriatic disease severity and adherence to the Mediterranean diet: a systematic review of observational studies	28
BT25: Dermatology and the metaverse: what’s on the horizon?	28
P74 Guselkumab clinical super-response is associated with faster normalization of blood and skin pathology: data from the Phase 3b GUIDE trial	28
Burden of atopic dermatitis in paediatric patients: an international cross-sectional study	27
514 - Tapinarof cream 1% once daily: significant efficacy in the treatment of atopic dermatitis in two pivotal phase 3 trials in adults and children down to 2 years of age	27
GD07: The use of the Dermatology Life Quality Index suite of patient‐reported outcome measures in neglected tropical diseases of the skin: a systematic review	27
Methotrexate and Cyclosporin Improve Skin Biomarkers in Paediatric Atopic Dermatitis: Results from the TREatment of Severe Atopic Eczema Trial	27
Editor's Choice – John Ingram – December 2023	27
Corrigendum	27
Risankizumab versus apremilast in the era of skin clearance	27
The relative contribution of the decreasing trend in tumour thickness to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population‐based investigation*	26
730 - Patient opinions on healthcare provider interactions and current treatment satisfaction in adults with atopic dermatitis by race and ethnicity	26
A guide to using the core outcome set for eczema	26
Decreased quality of life in people with psoriasis and psoriatic arthritis vs. people with psoriasis alone: data from a national US survey	26
BH13 Current wig prescribing practices and financial evaluation in a National Health Service foundation trust: lessons learnt and future challenges	26
‘Substantial clinical benefit’ and ‘substantial clinical worsening’ cutoff of Vitiligo Impact Scale (VIS)-22 change scores	26
H20 Sarcoptes scabiei: to solve the current crisis, hunt for clues in our past	26
705 - Patient preferences for atopic dermatitis treatment profiles: results from a discrete choice experiment	26
Poster presentationsPA10 Hidradenitis suppurativa and trisomy 21: a case series	25
H19 Not only a finder of ‘solutions’: Max Jessner, Holocaust survivor and discoverer of Jessner–Kanof lymphocytic infiltrate	25
DS17 Two cases of traumatic pseudoaneurysm of the superficial temporal artery	25
H06 The changing face of skin disease in warfare: from World War I to modern times	25
DS23 Evaluation of American Joint Committee on Cancer and alternative tumour classification systems for primary penile squamous cell carcinoma	24
O05 Risk of keratinocyte carcinomas in patients with psoriasis treated with biologic therapy: analysis from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR),	24
DS24 Is surgery the best management for keratoacanthoma centrifugum marginatum?	24
SG08 The phenotypic spectrum of MBTPS2 mutations: two illustrative cases	24
P093 Bespoke omalizumab prescribing in chronic spontaneous urticaria	24
Poster presentationsBT15 Ethical implications of artificial intelligence in dermatology: use-case analysis of skin cancer diagnostic smartphone apps	24
P068 A history of mycosis fungoides: from Alibert to mogamulizumab	24
519 - Efficacy of prolonged ruxolitinib cream treatment for vitiligo among patients with limited or no initial response at 6 months	24
PA12 Fats and figures: how abnormal lipids unravel the truth	23
BH09 Mycophenolate mofetil in the management of lichen planus pigmentosus in a woman with frontal fibrosing alopecia	23
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study	23
Consensus on the clinical management of chronic radiation dermatitis and radiation fibrosis: a Delphi survey	23
The future of patient-reported outcome measurement in hyperhidrosis lies in thoughtful, evidence-based implementation	23
Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma	23
UK trends in work-related contact dermatitis caused by nickel, chromium and cobalt	23
Real‐world experience of off‐label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna	23
Cemiplimab‐rwlc in advanced cutaneous squamous cell carcinoma: real‐world experience in a French dermatology department	23
Correction to: Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded c	22
Evaluating the role of histopathology in diagnosing pyoderma gangrenosum using Delphi and PARACELSUS criteria: a multicentre, retrospective cohort study	22
Sensitive and specific assay for the serological diagnosis of anti-p200 pemphigoid based on the recombinant laminin β4 subunit	22
Response to ‘Decline in the use of phototherapy in France from 2010 to 2019’	22
Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study	22
Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry	22
High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa	21
Proliferative actinic keratoses are associated with adverse clinical outcomes relative to actinic keratoses without a proliferative growth pattern	21
Expanding the SLURP1 disease spectrum: from Mal de Meleda to palmoplantar keratoderma/progressive symmetric erythrokeratoderma	21
FC26 The MEditerranean Diet and Time-Restricted Eating Dietary Interventions for Psoriasis (METRED-P) study: an interim analysis of the first UK-based diet intervention trial	21
Missing melanomas in England during the COVID-19 pandemic: 2485 fewer melanoma diagnoses in 2020 than in 2019	21
CD02: Cutaneous reactions to glucose sensors: is the problem stuck with us?	21
Clinical practices and educational interests of dermatologists in Caribbean countries	21
WNT10A , dermatology and dentistry	21
FC09 Clinical and immunomodulatory effects of mesenchymal stromal cells in multiple biologic-refractory psoriasis	21
DP10: A case of reactive angioendotheliomatosis with resolution following improved glycaemic control	21
In desmosomes direct inhibition precedes p38MAPK-mediated uncoupling to reduce Dsg3 adhesion by pemphigus autoantibodies	21
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials	21
The antidiabetic medicine metformin has beneficial effects in hidradenitis suppurativa	21
Using patient and melanoma tissue information to predict the risk of cancer spreading to the lymph nodes (CP‐GEP tool)	21

P40: Histopathological features of orofacial granulomatosis with and without underlying gut Crohn disease	20
Safety of long‐term treatment with risankizumab in patients with moderate‐to‐severe plaque psoriasis	20
CD20: Occupational dermatitis virtual clinic for healthcare workers: clinics to increase training opportunities to dermatology registrars who are working from home	20
PA10: Written action plans to support the self‐management of eczema: findings from an international review	20
我们如何评估前额纤维化性脱发的严重程度和治疗?	20
BG02 (P35): Alterations of forces applied under the feet in patients with epidermolysis bullosa simplex during gait	20
‘Quantity does not make quality’: when is there a case for repeating a network meta‐analysis?	20
DT07: The impact of the COVID‐19 pandemic on dermatology ST3 application preparation: a national survey of junior doctors in the UK	20
BT11: Lesions in lockdown: mobile dermoscopy in virtual dermatology clinics	20
影响皮肤的淋巴瘤的数量和类型的最新变化	20
Chronic wounds in patients with epidermolysis bullosa who have had bone marrow transplantation can be healed by skin grafts from the same donor	20
便于充分了解炎症后色素沉着的模型	20
P24: Benzalkonium chloride: a potential emerging allergen in the era of the COVID‐19 pandemic	19
PA02 (P28): Prediction of FLG genotype using human and computer‐aided phenotype extraction with random forest machine learning	19
DS24: Clinical outcomes of cutaneous squamous cell carcinomas treated with Mohs micrographic surgery	19
P34: Exploring anaemia in hidradenitis suppurativa: a comparative study and proposal of a clinical pathway	19
P55: Post‐COVID analysis of 2‐week wait face‐to‐face activity and the potential for a teledermatology service	19
BG12: Cicatricial junctional epidermolysis bullosa: a forgotten subtype	19
阳光与新冠肺炎死亡风险较低有关, 但并非因为维生素 D	19
Adcitmer ® 是 Merkel 细胞癌的潜在治疗方法	19
Implementing evidence-based strategies to optimize the journey of patients with hidradenitis suppurativa	19
转移性黑色素瘤免疫治疗后患者恢复生活的经验	19
H12: Campbell De Morgan: doctor, scientist, polymath	19
Editor’s Choice	19
Patient experiences of living with vulval lichen sclerosus	19
CD03: Practical use of a limonene and linalool series	19
Review of different staging systems for cutaneous squamous cell carcinoma	19
P43: Desmoplasia in cutaneous squamous cell carcinoma with perineural invasion	18
DS12: Replacing the need for skin grafting in small surgical excision wounds	18
Creating the Scale of Alopecia Areata Distress to measure a wide range of negative emotional, social and relationship disease consequences in adults	18
体重在 90 公斤或以上的银屑病患者获益于更为频繁的苏金单抗给药	18
P21: Practising dermatology in the era of COVID‐19: a tertiary centre’s experience of adapting to change	18
Considerations in association studies in dermatoepidemiology	18
P28: The effects of COVID‐19 on undergraduate dermatology training: a qualitative study	18
Varied skin reactions after COVID-19 vaccination	18
BT14: Exploring the feasibility of a remote acne service: a report of a pilot study using the MySkinSelfie platform during the COVID‐19 pandemic	18
BT07: ‘To see or not to see?’ That is the question: teleconsultations in primary care and the impact on 2‐week‐wait referrals and outcomes	18
P33 Investigating the utility and exploring biological targets of micro-wound healing compounds in 2D and 3D skin models	18
Insights into the biological differences in hair follicles of men with androgenetic alopecia	18
Hidradenitis suppurativa: BJD state-of-the-art review series	17
FC16 Blood mass cytometry reveals Type 1 cytokine expression in blood of patients with paradoxical eczema secondary to biologics for psoriasis	17
P05 Pre-visit online paediatric atopic dermatitis questionnaire – a feasibility study	17
Genetic basis of a novel rare dominant form of palmoplantar keratoderma	17
428 Evaluating chronic pruritus prevalence, characteristics and effects on atopic dermatitis patients from a referral university hospital in São Paulo, Brazil: a cross-sectional study	17
Lived experiences of patients with hidradenitis suppurativa-related pain	17
P111 An AI-assisted similarity search engine for enhanced psoriasis case identification and patient engagement	17
Tinea capitis in China	17
P17 Pseudomonas infection causing acute painful flexural exacerbation in a child with IFAP syndrome	17
649 - Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials	17
Correction to: Comment on ‘Treatment of moderate-to-severe alopecia areata in preadolescent children with baricitinib’: authors’ reply	17
Greater understanding about a rare inherited skin disorder from a study of NLRP1 in two sisters with different severity of disease	17
O01 Inborn errors of metabolism - Solving the puzzle of prolidase deficiency	17
A review of genetic hair disorders	17
Parent and child experiences of skin conditions and views on mindfulness-based support	17
PS02 (P16): Gender and sexual identity: unmet dermatological needs of LGBTQ + individuals and how dermatologists can provide better care: a qualitative analysis of a	17
A clinical trial in children and young people with severe eczema comparing methotrexate with ciclosporin	16
DE04 Large-scale virtual dermatology teaching for internal medical trainees across the UK	16
P15 Progressive papulonodular eruption following COVID-19 infection: a rare diagnosis and review of the literature	16
DS21 Patients’ experience with one-stop skin cancer clinics	16
DP02 (P30) Declining staff numbers and increasing workload: is there a solution?	16
P45 An analysis of infantile haemangioma referrals and comparison with the infantile haemangioma European task force’s ‘infantile haemangioma referral score’	16
Focusing on antigen-specific T cells	16
DS28 In search of salivation? Management of parotid duct injury following Mohs micrographic surgery	16
DE02 Honing in on clinician needs: a grassroots development of an educational resource for dermatologists	16
Prolyl-tRNA synthetase inhibitor as a novel first-in-class keloid treatment: Downregulation of de novo collagen synthesis and inflammatory cascade	15
309 Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest	15
P53 Incidence of merkel cell carcinoma in the Republic of Ireland (1994–2019)	15
BI30 Remission of a large plantar verruca vulgaris in an immunocompromised patient postincisional punch biopsy	15
Correction to: Microbiome characterization of skin biopsies in Spanish patients with hidradenitis suppurativa shows a decrease in D1 and H1 lineages of Cutibacterium acnes	15
Epidermal necrolysis: a chronic disease associated with loss-of-life expectancy and lifetime healthcare expenditure	15
BI24 Cutaneous pseudolymphoma secondary to pembrolizumab	15
Diverse approaches to the diagnosis and treatment of paediatric vitiligo: a survey of paediatric dermatologists	15
BG11: Vulval intraepithelial neoplasia and early squamous cell carcinoma development in a patient with Netherton syndrome	15
343 Dupilumab efficacy on itch and skin lesions in adult patients with prurigo nodularis may be observed concurrently or independently over 24 weeks: results from two phase 3 trials	15
698 - Impact of amlitelimab (an anti-OX40 ligand antibody) on clinical outcome assessments for atopic dermatitis: results from the 52-week STREAM-AD phase 2b study in adults with moderate-to-severe at	15
Integrative serum proteomics analysis reveals distinct immune and cardiovascular profile dysregulation in erythrodermic psoriasis	15
326 Dupilumab: a comparison of infection rates across atopic dermatitis trials in adults, adolescents, children and infants	15
BH03 Lipoedematous scalp occurring in two female siblings: further evidence of a genetic role?	15
Atopic dermatitis, hypertension and cardiovascular disease	15
Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials	15
Development and preliminary validation of the patient-reported Chronic Itch Burden Scale assessing health-related quality of life in chronic pruritus	15
Dermatitis cruris pustulosa et atrophicans	14
P088 Physician-assessed effectiveness, patient-reported outcomes, and safety in adult and adolescent patients with atopic dermatitis treated with dupilumab: real-world insights 1 year into the GLOBOST	14
Levelling up outcomes in atopic dermatitis through personalized dosing of upadacitinib	14
Semi-virtual patch testing: the future?	14
Younger facial looks are associate with a lower likelihood of several age-related morbidities in the middle-aged to elderly	14
PS06 Mindfulness-based stress reduction alleviates flushing and negative emotions in rosacea: an exploratory study	14
The impact of hidradenitis suppurativa on professional life	14
On the potential beneficial effects of indoor tanning	14
Risk of nonacral cutaneous melanoma after the diagnosis of acral melanoma	14
Haematohidrosis	14
Artificial daylight photodynamic therapy using methyl aminolaevulinate in a real-world setting in Germany: results from the noninterventional study ArtLight	14
Progression of in situ and early invasive cutaneous squamous cell carcinomas concurrent with successful target tumour response to a programmed death-1 inhibitor	14
Strongyloides screening prior to dupilumab therapy in atopic dermatitis: a retrospective cohort study evaluating screening utility	14
Head lice: evidence that resistance to physically acting treatments is developing	14